Showing 118 of 118on this page. Filters & sort apply to loaded results; URL updates for sharing.118 of 118 on this page
Clinical Trial: AZD2936 for Non-Small Cell Lung Cancer (NCT04995523 ...
AZD2936 for Non-Small Cell Lung Cancer Clinical Trial 2024 | Power
AZD2936 for Non-Small Cell Lung Carcinoma (NSCLC) Clinical Trial 2022 ...
Estudio sobre el anticuerpo bispecífico AZD2936 en pacientes con cáncer ...
ARTEMIDE-01: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific ...
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in ...
AZD2936 for Non-Small Cell Lung Cancer Clinical Trial 2025 | Power
Study of Rilvegostomig (AZD2936) for Adults with Advanced or Metastatic ...
rilvegostomig (AZD2936) / AstraZeneca, Compugen, Xoma
阿斯利康双特异性抗体AZD2936亮相：PD-1与TIGIT双管齐下，探索抗癌新路径_摩熵医药
Rilvegostomig bei nicht-kleinzelligem Lungenkrebs
AZD2936获NSCLC临床批准，阿斯利康对TIGIT靶点发起挑战 - 脉脉
双抗才是“下一个PD-(L)1”的正确打开方式？！阿斯利康PD-1×TIGIT进入临床 - 知乎
【AACR 2023】ADC药物”角力”AACR - 企业动态 - 丁香通
Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in ...
阿斯利康双特异性抗体AZD2936亮相：PD-1与TIGIT双管齐下，探索抗癌新路径_摩熵医药(原药融云)
ESMO 2023: Discussant - MEDI5752 (Volrustomig) for 1st Line Advanced ...
Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer ...
速递 | 治疗晚期非小细胞肺癌，阿斯利康PD-1/TIGIT双特异性抗体启动2期临床 - Py学习
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary ...
奥希替尼联合化疗：阿斯利康宣布 III 期 FLAURA2 临床试验成功，一线治疗 NSCLC
PM8002联合化疗一线治疗肺痞的Ph2/3期临床设计 - 2025年08月 - 行业研究数据 - 小牛行研
肺癌新药临床试验：PD-1/TIGIT双抗AZD2936联合治疗-印塔健康官网
1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a ...
阿斯利康PD-1/TIGIT双抗Rilvegostomig即将迈入临床III期！_腾讯新闻
TIGIT in Lung Cancer: Potential Theranostic Implications
Pharmaceutics | Free Full-Text | Bispecific Antibodies in Cancer ...
雷格苏米单抗rilvegostomig-药品详情-NextPharma®数据库-ByDrug-医药魔方数据库
Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates ...
B7H4 ADC + PARPi + PD-1/TIGIT 双抗，三联疗法国内获批临床_Insight_开发_治疗
List of anti-TIGIT trials registered in lung cancer | Download ...
肿瘤靶点 — TIGIT 本文是肿瘤靶点系列之一，肿瘤靶点大概分为5大类：1、肿瘤形成的靶点（形成/调控机制）；2、肿瘤生长的靶点（微环境 ...
Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort ...
:%0A%0AAZD2936%20for%20Non-Small%20Cell%20Lung%20Cancer.png?md=1)
,%20Lung%20Neoplasms,%20Carcinoma,%20Non-Small-Cell%20Lung:%0A%0AAZD2936%20for%20Non-Small%20Cell%20Lung%20Carcinoma%20(NSCLC).png?md=1)
